Search results
Showing 136 to 150 of 205 results for lymphoma
Discontinued Reference number: GID-TA10144
Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer (TA584)
Evidence-based recommendations on atezolizumab (Tecentriq) with bevacizumab (Avastin), carboplatin and paclitaxel for metastatic non-squamous non-small-cell lung cancer in adults.
In development Reference number: GID-TA11749 Expected publication date: 10 June 2027
Nelarabine for treating refractory T-cell lymphoblastic non-Hodgkin's lymphoma [ID1044]
Discontinued Reference number: GID-TA10087
Discontinued Reference number: GID-TA10859
Read biographies of the members of our quality standards advisory committee.
Read biographies of the members of our quality standards advisory committee.
Coeliac disease: recognition, assessment and management (NG20)
This guideline covers the recognition, assessment and management of coeliac disease in children, young people and adults.
Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) and chemotherapy for untreated metastatic non-small-cell lung cancer.
Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma [ID3975]
In development Reference number: GID-TA10858 Expected publication date: TBC
Find out more about the NICE technology appraisal advisory committee B members and their registered interests
Find out more about the NICE technology appraisal advisory committee B members and their registered interests
This guidance has been updated and replaced by NICE technology appraisal guidance 933. People already having tisagenlecleucel for relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies through the Cancer Drugs Fund can continue. For those people, it will be funded by the company until they and their NHS clinician consider it appropriate to stop.
Awaiting development Reference number: GID-TA11271 Expected publication date: TBC
Evidence-based recommendations on pembrolizumab (Keytruda) plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer in adults.